EUVIMEDEUVIMED entdecken
Klinische Studie

Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic

Niamh Kearney iD, Rosalind Hughes, Brian Kirby

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad130 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Niamh Kearney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Biological Products, Hidradenitis Suppurativa. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: N.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS) is characterized by increased interleukin (IL)-17A/C/F. Two open-label trials of brodalumab, an IL-17 receptor antagonist, have been completed, with 8 of 10 patients receiving brodalumab fortnightly and 10 of 10 patients receiving brodalumab weekly achieving 75% Hidradenitis Suppurativa Clinical Response. All patients were biologic ‘experienced’ but were not reported to have failed biologic treatment. We report outcomes for eight patients with HS who had failed at least one biologic, treated with brodalumab 210 mg fortnightly, to provide real-world evidence. Four of eight patients remain on brodalumab, with a mean treatment duration of 11.3 months. All patients who remain on brodalumab subjectively report continued treatment efficacy. The mean Dermatology Life Quality Index reduced from 20.6 to 16.8 at week 16. All patients required concurrent antibiotics due to flares. Brodalumab may be effective in patients who have previously failed multiple biologics, but efficacy in our real-world study falls short of the two open-label trials. This may reflect severe treatment-resistant disease. In the absence of further licensed treatments for HS, brodalumab may be a good option following adalimumab failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsHidradenitis SuppurativaHumansAdalimumabInterleukin InhibitorsSeverity of Illness IndexTreatment FailureTreatment OutcomeAntibodies, Monoclonal, Humanized

Substanzen

AdalimumabBiological ProductsInterleukin InhibitorsbrodalumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland.
  • UCD School of Medicine, University College Dublin, Dublin, Ireland.
  • UCD Charles Institute of Dermatology, University College Dublin, Dublin, Ireland.

ORCID-Profile: Niamh Kearney

Förderung

  • N.K.

Zitieren

APA

Kearney, N., Hughes, R., & Kirby, B. (2023). Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad130

Vancouver

Kearney N, Hughes R, Kirby B. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad130

BibTeX
@article{Kearney2023,
  author = {Kearney, Niamh and Hughes, Rosalind and Kirby, Brian},
  title = {Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad130}
}
Kostenlos starten →